Mereo BioPharma Group PLCNASDAQ:MREO
- LAST PRICE4.1550
- TODAY'S CHANGE (%)0.0750 (1.8382%)
- Bid / Lots4.1000/ 10
- Ask / Lots4.2000/ 2
- Open / Previous Close4.1600 / 4.0800
- Day Range
- 52 Week Range
- Volume469,126
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | MREO |
|---|---|---|
| 09:32 ET | 7539 | 4.14 |
| 09:34 ET | 4640 | 4.1086 |
| 09:36 ET | 14800 | 4.09 |
| 09:38 ET | 10571 | 4.04 |
| 09:39 ET | 4100 | 4.05 |
| 09:41 ET | 800 | 4.04 |
| 09:43 ET | 3129 | 4.05 |
| 09:45 ET | 2141 | 4.09 |
| 09:48 ET | 1200 | 4.105 |
| 09:50 ET | 1077 | 4.11 |
| 09:52 ET | 3300 | 4.1194 |
| 09:54 ET | 2100 | 4.12 |
| 09:56 ET | 4145 | 4.1 |
| 09:57 ET | 1200 | 4.105 |
| 09:59 ET | 100 | 4.09 |
| 10:01 ET | 2508 | 4.1 |
| 10:03 ET | 5730 | 4.105 |
| 10:06 ET | 400 | 4.095 |
| 10:08 ET | 300 | 4.1 |
| 10:12 ET | 6445 | 4.0801 |
| 10:14 ET | 396 | 4.07 |
| 10:15 ET | 1127 | 4.04 |
| 10:17 ET | 10051 | 4.03 |
| 10:19 ET | 3800 | 4.04 |
| 10:21 ET | 2611 | 4.04 |
| 10:24 ET | 1700 | 4.04 |
| 10:26 ET | 800 | 4.035 |
| 10:28 ET | 7247 | 4.03 |
| 10:30 ET | 1799 | 4.04 |
| 10:32 ET | 8502 | 4.015 |
| 10:33 ET | 6926 | 4.015 |
| 10:35 ET | 3500 | 4.0181 |
| 10:37 ET | 2483 | 4.015 |
| 10:39 ET | 12444 | 4.025 |
| 10:42 ET | 3419 | 4.025 |
| 10:44 ET | 3636 | 4.02 |
| 10:46 ET | 2877 | 4.025 |
| 10:48 ET | 300 | 4.01 |
| 10:50 ET | 1218 | 4.01 |
| 10:51 ET | 3417 | 4 |
| 10:53 ET | 1300 | 4.01 |
| 10:55 ET | 1200 | 4.0163 |
| 10:57 ET | 1100 | 4.02 |
| 11:00 ET | 2000 | 4.02 |
| 11:02 ET | 6700 | 4.0193 |
| 11:04 ET | 1100 | 4.01 |
| 11:08 ET | 11700 | 4.025 |
| 11:09 ET | 3000 | 4 |
| 11:11 ET | 7524 | 4 |
| 11:13 ET | 200 | 3.995 |
| 11:15 ET | 238 | 4 |
| 11:18 ET | 2926 | 3.9901 |
| 11:20 ET | 13016 | 3.9805 |
| 11:22 ET | 2469 | 3.98 |
| 11:24 ET | 2000 | 3.99 |
| 11:26 ET | 2986 | 4 |
| 11:27 ET | 1000 | 4.0075 |
| 11:29 ET | 1100 | 4.006 |
| 11:31 ET | 1200 | 4.0199 |
| 11:33 ET | 1250 | 4.025 |
| 11:36 ET | 1500 | 4.02 |
| 11:38 ET | 100 | 4.02 |
| 11:40 ET | 1600 | 4.04 |
| 11:42 ET | 2800 | 4.0201 |
| 11:44 ET | 2100 | 4.0325 |
| 11:47 ET | 1500 | 4.0347 |
| 11:51 ET | 300 | 4.04 |
| 11:54 ET | 416 | 4.025 |
| 11:58 ET | 843 | 4.03 |
| 12:00 ET | 2176 | 4.02 |
| 12:03 ET | 100 | 4.03 |
| 12:05 ET | 1461 | 4.035 |
| 12:07 ET | 8316 | 4.04 |
| 12:12 ET | 2009 | 4.03 |
| 12:14 ET | 1627 | 4.03 |
| 12:16 ET | 100 | 4.035 |
| 12:18 ET | 800 | 4.0473 |
| 12:34 ET | 2000 | 4.0499 |
| 12:36 ET | 4650 | 4.045 |
| 12:38 ET | 2700 | 4.0491 |
| 12:39 ET | 1552 | 4.04 |
| 12:43 ET | 400 | 4.045 |
| 12:45 ET | 100 | 4.045 |
| 12:50 ET | 1589 | 4.035 |
| 12:52 ET | 850 | 4.0333 |
| 12:56 ET | 100 | 4.03 |
| 12:57 ET | 900 | 4.038 |
| 12:59 ET | 200 | 4.035 |
| 01:03 ET | 558 | 4.03 |
| 01:06 ET | 900 | 4.04 |
| 01:12 ET | 1000 | 4.055 |
| 01:14 ET | 1732 | 4.0548 |
| 01:15 ET | 700 | 4.06 |
| 01:21 ET | 2234 | 4.055 |
| 01:24 ET | 600 | 4.0509 |
| 01:26 ET | 700 | 4.06 |
| 01:28 ET | 5784 | 4.07 |
| 01:30 ET | 300 | 4.08 |
| 01:32 ET | 613 | 4.08 |
| 01:33 ET | 2777 | 4.075 |
| 01:39 ET | 1775 | 4.075 |
| 01:42 ET | 600 | 4.075 |
| 01:44 ET | 700 | 4.075 |
| 01:46 ET | 2454 | 4.075 |
| 01:48 ET | 7132 | 4.09 |
| 01:50 ET | 3200 | 4.075 |
| 01:53 ET | 5000 | 4.075 |
| 01:57 ET | 300 | 4.075 |
| 02:02 ET | 6757 | 4.085 |
| 02:04 ET | 300 | 4.095 |
| 02:08 ET | 900 | 4.08 |
| 02:09 ET | 862 | 4.09 |
| 02:11 ET | 200 | 4.09 |
| 02:15 ET | 100 | 4.0911 |
| 02:18 ET | 102 | 4.095 |
| 02:20 ET | 772 | 4.085 |
| 02:22 ET | 100 | 4.085 |
| 02:26 ET | 132 | 4.085 |
| 02:31 ET | 100 | 4.08 |
| 02:33 ET | 100 | 4.08 |
| 02:38 ET | 5545 | 4.0782 |
| 02:40 ET | 1024 | 4.085 |
| 02:42 ET | 3177 | 4.09 |
| 02:44 ET | 700 | 4.09 |
| 02:51 ET | 1000 | 4.09 |
| 02:58 ET | 100 | 4.095 |
| 03:00 ET | 2201 | 4.095 |
| 03:02 ET | 1889 | 4.105 |
| 03:03 ET | 800 | 4.105 |
| 03:05 ET | 748 | 4.11 |
| 03:07 ET | 14659 | 4.125 |
| 03:09 ET | 800 | 4.125 |
| 03:12 ET | 974 | 4.1297 |
| 03:14 ET | 800 | 4.13 |
| 03:16 ET | 1845 | 4.125 |
| 03:18 ET | 600 | 4.1282 |
| 03:20 ET | 500 | 4.1284 |
| 03:21 ET | 2900 | 4.125 |
| 03:23 ET | 600 | 4.125 |
| 03:25 ET | 4259 | 4.145 |
| 03:27 ET | 6437 | 4.1593 |
| 03:30 ET | 2220 | 4.16 |
| 03:32 ET | 5007 | 4.145 |
| 03:34 ET | 3984 | 4.14 |
| 03:36 ET | 3500 | 4.14 |
| 03:38 ET | 1347 | 4.145 |
| 03:39 ET | 1300 | 4.135 |
| 03:41 ET | 2567 | 4.145 |
| 03:43 ET | 2050 | 4.145 |
| 03:45 ET | 3142 | 4.15 |
| 03:48 ET | 1291 | 4.15 |
| 03:50 ET | 5855 | 4.14 |
| 03:52 ET | 6367 | 4.165 |
| 03:54 ET | 4650 | 4.155 |
| 03:56 ET | 4937 | 4.155 |
| 03:57 ET | 1902 | 4.16 |
| 03:59 ET | 3063 | 4.155 |
Jul 22, 2024
DJ Mereo BioPharma Group Price Target Maintained With a $7.00/Share by Cantor Fitzgerald, from 11:52AM ET on Monday Jul 22, 2024 by Dow Jones
11:52AM ET on Monday Jul 22, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Mereo BioPharma Group PLC | 623.4M | -13.0x | --- |
Stoke Therapeutics Inc | 758.9M | -6.6x | --- |
Dianthus Therapeutics Inc | 824.4M | -9.1x | --- |
Mesoblast Ltd | 858.5M | -5.1x | --- |
CARGO Therapeutics Inc | 811.5M | -6.1x | --- |
Rapport Therapeutics Inc | 812.4M | -15.9x | --- |
Company Information
Mereo BioPharma Group plc is a biopharmaceutical company. It is focused on the development of therapeutics for rare diseases. It has developed a portfolio of clinical-stage product candidates. The Company has two rare disease product candidates: setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat for the treatment of severe alpha-1-antitrypsin deficiency-associated lung disease (AATD-LD) and bronchiolitis obliterans syndrome (BOS). It also has two oncology product candidates in clinical development. It also includes Etigilimab, an antibody against TIGIT (T-cell immunoreceptor with Ig and ITIM domains). Its non-core partnered programme, Navicixizumab, is a bispecific antibody that inhibits delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF). Its non-core programs available for partnership include Acumapimod and Leflutrozole. Acumapimod is a p38 MAP kinase inhibitor therapy for treatment during severe acute exacerbations of COPD (AECOPD).
Contact Information
- Headquarters
- One Cavendish Place, Fourth FloorLONDON, United Kingdom W1G0QF
- Phone
- ---
- Fax
- ---
Executives
- Non-Executive Independent Director
- Michael Wyzga
- Chief Executive Officer, Director
- Denise Scots-Knight
- Chief Financial Officer
- Christine Fox
- Senior Vice President - Clinical Development
- Suba Krishnan
- Senior Vice President - Therapeutic Head
- Jackie Parkin
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $623.4M |
|---|---|
Revenue (TTM) | $10.2M |
Shares Outstanding | 152.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.87 |
EPS | $-0.32 |
Book Value | $0.45 |
P/E Ratio | -13.0x |
Price/Sales (TTM) | 61.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -416.58% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
